HIVD reviews applications involving innate and adaptive immune responses to HIV. This includes basic, preclinical, and clinical studies that pertain to host immune responses and dysfunction, and studies addressing immunological mechanisms relevant to HIV infection, pathogenesis, and persistence. HIVD also reviews applications addressing the development and delivery of candidate HIV vaccines and immune based therapies.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Mechanisms of immune activation, dysfunction, and senescence in HIV/AIDS.
- Mechanisms of immune control of HIV replication.
- Immunopathogenesis of HIV infection in tissues, including the digestive tract, genital tract, lymphatic system, and nervous system.
- Development and preclinical testing of immunological interventions to eliminate latent/persistent reservoirs, reduce immune dysfunction and/or restore immunity.
- Immunological mechanisms of spontaneous HIV control or non-progression.
- Effects of the microbiome on immune responses and HIV transmission and pathogenesis.
- Identification and development of potential vaccine epitopes, immunogens, or vectors.
- Assessment of new candidate vaccines in animal models and correlates of vaccine-induced immunity in animal models and humans.
- Strategies to elicit and/or characterize broadly neutralizing antibodies and assess them for prevention and therapy.
- Adjuvants to stimulate vaccine-induced immunogenicity and antibody maturation/function.
Shared Interests and Overlaps
HIV Molecular Virology, Cell Biology, and Drug Development (HVCD): Applications addressing the molecular or structural biology of anti-HIV restriction factors, the molecular biology of HIV latency establishment or reactivation, and the structural biology of HIV immunogens are reviewed in HVCD. Studies addressing preclinical development of non-immune based therapies for HIV are also reviewed in HVCD.
HIV Coinfections and HIV Associated Cancers (HCAC): Applications that address immunity and pathogenesis of HIV/AIDS associated pathogens or immune-based therapeutics for HIV associated coinfections and cancers may be reviewed in HCAC, if there is a clear and compelling HIV/AIDS context.
HIV Comorbidities and Clinical Studies Study Section (HCCS): Applications that address clinical studies of inflammation and its contribution to organ disease, clinical studies of organ-based viral reservoirs and interventions to eliminate them, and non-immunological effects of drug abuse on the CNS and other organs in the context of HIV/AIDS are reviewed in HCCS.
Only applications in which there is a clear and compelling HIV/AIDS research component in the proposed research plan are eligible for the AIDS deadlines and review in HIVD and other AARR study sections. Those deemed insufficiently related to HIV/AIDS are assigned to other study sections and must be submitted in time to meet the regular non-AIDS application due dates. Applicants might consider the following study sections:
Vaccines Against Microbial Diseases Study Section (VMD): VMD reviews applications concerned with vaccine development against all classes of pathogens except human immunodeficiency virus (HIV).
Immunity and Host Defense Study Section (IHD): IHD reviews applications concerned with the innate and adaptive immune responses to non-HIV and non-AIDS associated pathogens and commensals, including viruses, bacteria, fungi, and parasites.
Innate Immunity and Inflammation Study Section (III): III reviews applications addressing fundamental aspects of innate immunity including the enhancement of vaccine-induced immunogenicity.
Virology B Study Section (VIRB): VIRB reviews applications addressing fundamental aspects of non-HIV viral immunity and pathogenesis.